Alzheimer’s disease has wrecked the hopes of countless drug researchers as thoroughly as the lives of its many sufferers. But persistence pays. Eli Lilly’s new drug donanemab significantly slows memory loss, the US company revealed this week. It is on track to win the second approval this year of a drug capable of altering the course of the disease.
阿茲海默症曾像徹底摧毀許多患者的生命那樣徹底摧毀無數藥物研究人員的希望。但堅持終獲回報。美國禮來公司本週透露，該公司的新藥donanemab可顯著減緩記憶喪失。該公司有望在今年獲得對能夠改變疾病進程的藥物的第二次批准。
您已閱讀15%（462字），剩餘85%（2687字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。